¿ Compugen Ltd., of Tel Aviv, Israel, said it has been approved to list its shares on the Tel Aviv Stock Exchange (TASE) to begin trading on Jan. 7. Mor Amitai, president and CEO of Compugen, said Compugen is the first biotechnology company to be traded on the TASE, reflecting the growth and significant market potential of biotechnology in Israel. Advantages of a dual listing include a longer trading day and access to the lower trading costs on the Tel Aviv Continuous Trading system. Compugen, founded in 1993, with a current market capitalization of $103 million, is the 17th company to take advantage of the relaxed dual listing legislation.
¿ Medical Marketing International Group plc, of Cambridge, UK, a technology management company, formed a joint venture company with the Northwick Park Institute for Medical Research in London to commercialize the discovery at Northwick of the role of carbon monoxide in the control of cardiovascular function. The venture will focus on the discovery of molecules that can carry and release carbon monoxide in a controlled fashion.